Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CALCA | P06881 | 5/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.32 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.32 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14064675 | 0.91 | CYP2C9 (0.40) | CYP2C9KCNH2CALCAEGLN1KCNE1 | |
| SCHEMBL5620668 | 0.89 | CYP2C9 (0.43) | CYP2C9KCNH2CALCAKCNE1CCR1 | |
| SCHEMBL4832734 | 0.88 | CYP2C9 (0.41) | CYP2C9KCNH2CALCAEGLN1KCNE1 | |
| SCHEMBL4830816 | 0.87 | KCNH2 (0.42) | CYP2C9KCNH2CALCAEGLN1KCNE1 | |
| SCHEMBL4828757 | 0.87 | KCNH2 (0.50) | CYP2C9KCNH2CALCAKCNE1CCR1 | |
| SCHEMBL4826958 | 0.84 | CYP2C9 (0.37) | CYP2C9KCNH2CALCA | |
| SCHEMBL4826770 | 0.84 | CYP2C9 (0.37) | CYP2C9KCNH2CALCAANO1 | |
| SCHEMBL5013185 | 0.84 | CYP2C9 (0.39) | CYP2C9KCNH2CALCAEGLN1KCNE1 | |
| SCHEMBL4826931 | 0.83 | CYP2C9 (0.38) | CYP2C9KCNH2CALCAEGLN1KCNE1 | |
| SCHEMBL4826458 | 0.83 | CYP2C9 (0.38) | CYP2C9KCNH2CALCAEGLN1KCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419969-B2 | HIV integrase inhibitors: cyclic pyrimidinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-02 | — | — | US | claimed |
| US-20060106007-A1 | HIV integrase inhibitors: cyclic pyrimidinone compounds | ROBERT BOSCH GMBH (DE) | 2006-05-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106007-A1 | HIV integrase inhibitors: cyclic pyrimidinone compounds | TYMP, TYMS, SAMHD1 | CYP2C9 1079/4885KCNH2 3435/4885CALCA 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.